Quanex Building Products Corp. (NYSE:NX) shares soared in Thursday's extended trading after the company released its fourth quarter earnings report, beating analyst estimates. Here's a look at the key figures from the quarter. NX stock is moving. Watch the price action here.The Details: Quanex reported quarterly earnings of 83 cents per share, which beat the analyst estimate of 52 cents by 61.17%, according to data from Benzinga Pro.Quarterly revenue came in at $489.8 million, which beat the consensus estim ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Financial Performance - Net sales for Q4 2025 were $489.8 million, a decrease of 0.5% compared to $492.2 million in Q4 2024, while full-year net sales increased by 43.8% to $1.84 billion from $1.28 billion in 2024[4] - The company reported a net loss of $250.8 million for the full year 2025, primarily due to a non-cash goodwill impairment[5] - Net income for the three months ended October 31, 2025, was $19,571,000, resulting in a diluted EPS of $0.43, compared to a net loss of $13,917,000 and an EPS of $(0.30) for the same period in 2024[32] - The company reported a net loss of $250.806 million for the twelve months ended October 31, 2025, compared to a net income of $33.059 million in 2024[17] - The company reported an operating loss of $193.952 million for the twelve months ended October 31, 2025, primarily due to goodwill impairment charges of $302.284 million[38] Revenue and Sales Breakdown - The Hardware Solutions segment saw a 1.4% increase in Q4 2025 net sales, while the Extruded Solutions segment experienced a 6.4% decrease[4] - Net sales for the three months ended October 31, 2025, were $489.846 million, a slight decrease from $492.161 million in the same period of 2024[32] - For the twelve months ended October 31, 2025, net sales reached $1.838 billion, compared to $1.278 billion in 2024, reflecting a significant increase of 43.8%[44] - Hardware Solutions generated $226.883 million in sales for the three months ended October 31, 2025, up from $223.712 million in 2024[44] - Extruded Solutions reported $168.603 million in sales for the three months ended October 31, 2025, compared to $180.135 million in the same period of 2024[44] - Custom Solutions achieved $103.401 million in sales for the three months ended October 31, 2025, slightly up from $101.240 million in 2024[44] Profitability Metrics - Gross margin for Q4 2025 was $137.6 million, representing a gross margin percentage of 28.1%, up from 23.8% in Q4 2024[2] - Adjusted EBITDA for the full year 2025 was $242.9 million, with an adjusted EBITDA margin of 13.2%, compared to $182.4 million and 14.3% in 2024[2] - EBITDA for the three months ended October 31, 2025, was $70,918,000, compared to $81,050,000 for the same period in 2024, while the twelve-month EBITDA was $242,890,000, up from $182,383,000[32] - The adjusted EBITDA for the twelve months ended October 31, 2025, was $242.890 million, compared to $182,383,000 in the previous year, indicating growth in operational performance[32] - The company reported a gross margin of $206.193 million for the twelve months ended October 31, 2025, with a gross margin percentage of 24.5%[38] Cash Flow and Debt Management - Cash provided by operating activities increased by approximately 86% year-over-year to $164.9 million in 2025[2] - The company repaid $75 million in bank debt during fiscal 2025, improving its liquidity to $372.4 million as of October 31, 2025[3][6] - As of October 31, 2025, total debt stood at $703.9 million, with a leverage ratio of 2.6x[5] - The company’s net debt as of October 31, 2025, was $627.851 million, down from $679.182 million in 2024[25] - Cash provided by operating activities for the twelve months ended October 31, 2025, was $164.897 million, compared to $88.812 million in 2024[22] Future Outlook - The company anticipates a cautious outlook for fiscal 2026, projecting flat revenue and EBITDA compared to fiscal 2025, with potential challenges in the first half[8] - The integration of the Tyman acquisition is substantially complete, with an expected realization of approximately $45 million in cost synergies over time[3] Cost Management - Selling, general and administrative expenses for the three months ended October 31, 2025, were $69.008 million, compared to $86.891 million in the same period of 2024[37] - The company incurred restructuring charges of $10.191 million for the twelve months ended October 31, 2025[38] - Interest expense for the twelve months ended October 31, 2025, was $55,812,000, compared to $20,593,000 in the previous year, reflecting increased borrowing costs[33] Impairment and Charges - The company’s goodwill impairment charges for the twelve months ended October 31, 2025, amounted to $302.284 million[22] - The company reported a goodwill impairment charge of $302,284,000 for the twelve months ended October 31, 2025, which impacted overall profitability[32]

Net Sales Growth of ~44% Year-Over-Year $75 Million of Debt Repaid in Fiscal 2025Cash Provided by Operating Activities Increased ~86% Year-Over-YearHealthy Balance Sheet and Strong LiquidityIntegration of Transformative Acquisition Substantially Complete and Thesis Remains Intact HOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Quanex Building Products Corporation (NYSE:NX) (“Quanex” or the “Company”) today announced its results for the three months and twelve months ended October 31, 2025. The Company reported ...

Core Insights - Quanex Building Products Corporation (NX) announced a significant acquisition of Tyman, which is expected to nearly double its business size [1] Group 1: Acquisition Details - The acquisition of Tyman is a massive purchase that raises questions regarding its impact on Quanex's operations and financials [1] Group 2: Investment Opportunities - The investment group "Value In Corporate Events" focuses on identifying actionable ideas from major corporate events such as mergers and acquisitions, earnings reports, and IPOs [1]

Core Viewpoint - Quanex Building Products Corporation is set to release its fourth quarter and full year 2025 results on December 11, 2025, after market close [1] - A conference call to discuss the results is scheduled for December 12, 2025, at 11:00 a.m. ET [2] Company Overview - Quanex is a global manufacturer with capabilities across various end markets, including window, door, solar, refrigeration, custom mixing, building access, and cabinetry [3] - The company collaborates with leading OEMs to provide innovative solutions and plans to leverage its material science expertise to expand into adjacent markets [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Quanex Building Products Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Quanex securities between December 12, 2024, and September 5, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3][6]. - The lawsuit claims that Quanex made false and misleading statements regarding its operations, particularly concerning the maintenance of tooling and equipment at its Tyman Mexico facility, which were significantly underinvested [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering substantial amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements achieved [4]. Group 3: Case Specifics - The lawsuit alleges that Quanex's tooling and equipment conditions had degraded to near catastrophic levels, leading to significant costs and delays in expected benefits from the Tyman integration [5]. - It is claimed that Quanex had previously identified these issues, and the positive statements made by the defendants about the company's business were materially misleading [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Quanex Building Products Corporation to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to misleading statements made during the Class Period from December 12, 2024, to September 5, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased Quanex securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and potential lead plaintiffs must move the Court by November 18, 2025 [3]. - The lawsuit alleges that Quanex made false and misleading statements regarding its tooling and equipment maintenance, which were significantly underinvested, leading to degraded conditions and potential significant costs [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [4].

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Skye Bioscience, Inc. (NASDAQ: SKYE) on behalf of investors who suffered significant losses during the specified Class Period from November 4, 2024, to October 3, 2025, due to alleged misleading statements regarding the company's business operations [1][3]. Allegations - The lawsuit claims that Skye Bioscience made materially false and misleading statements about its business, specifically regarding the effectiveness of its drug nimacimab, which was overstated, leading to inflated clinical, regulatory, and commercial prospects [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file motions by January 16, 2026, and can choose to remain absent class members without participating in the case [4]. Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception, and operates on a contingency fee basis, meaning shareholders incur no fees or expenses [6].

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with deadlines for filing lead plaintiff motions set for November 18, 2025 [1] Quanex Building Products Corporation (NYSE: NX) - Class period spans from December 12, 2024, to September 5, 2025, with allegations of materially false and misleading statements made by defendants [2] - Key issues include significant underinvestment in tooling and equipment maintenance at the Tyman Mexico facility, leading to degraded conditions and potential significant costs that could delay expected benefits from the Tyman integration [2] Jasper Therapeutics, Inc. (NASDAQ: JSPR) - Class period runs from November 30, 2023, to July 3, 2025, with similar allegations of misleading statements and undisclosed adverse facts [3] - Defendants failed to disclose lack of necessary controls for third-party manufacturers, increasing risks to ongoing studies and overstating the company's business and financial prospects [3] KBR, Inc. (NYSE: KBR) - Class period is from May 6, 2025, to June 19, 2025, with allegations of misleading statements regarding the partnership with TRANSCOM and its ability to fulfill contracts [5] - Defendants claimed no issues with the partnership despite known material concerns, leading to misleading statements about the company's operations and prospects [5]